In a nutshell This study evaluated the effectiveness of osimertinib (Tagrisso) in patients over age 80 with advanced small cell lung cancer (NSCLC). This study found that these elderly patients had similar outcomes to patients in clinical trials. Some background NSCLC is the most common type of lung cancer. One common treatment is...
Read More
In a nutshell This article investigated the safety and effectiveness of stereotactic body radiotherapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). The authors concluded that SBRT is safe and effective for these patients. Some background NSCLC is the most common kind of lung cancer. Patients with...
Read MoreIn a nutshell This study investigated the effect of local consolidative therapy (LCT) with radiotherapy or surgery in patients with advanced non-small cell lung cancer (NSCLC). They found that LCT prolonged survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Metastatic...
Read MoreIn a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read MoreIn a nutshell This trial is examining the effectiveness and safety of standard chemoradiation vs a PET base chemoradiation combination in patients with non-small cell lung carcinoma (NSCLC). The main outcomes to be measured will be side effects and survival without cancer growing or spreading. The details A treatment option for...
Read MoreIn a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...
Read MoreIn a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...
Read MoreIn a nutshell This phase 3 trial is examining the effectiveness of durvalumab (Imfinzi) combined with chemotherapy vs chemotherapy alone for stage II and III non-small cell lung cancer (NSCLC) before surgery. The main outcome to be measured will be the major pathological response (mPR; 10 percent or fewer alive cancer cells...
Read More
In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....
Read MoreIn a nutshell This phase 3 trial will investigate the safety and effectiveness of osimertinib (Tagrisso) after chemoradiation (CR) in non-small cell lung cancer (NSCLC). The main outcome will be progression-free survival (PFS; survival without cancer growing or spreading). The details Non-small cell lung cancer (NSCLC) is the most...
Read More
In a nutshell This study evaluated the effectiveness of adding cetuximab (Erbitux) to standard chemotherapy and radiotherapy treatment for advanced non-small cell lung cancer (NSCLC). This study found that adding cetuximab to chemotherapy and radiotherapy resulted in promising outcomes. Some background NSCLC is the...
Read More
